Form 4: Edwards Lifesciences CFO Sells Shares Under 10b5-1 Plan

Edwards Lifesciences' Chief Financial Officer, Scott B. Ullem, exercised stock options and sold 7,700 shares of common stock under a pre-arranged trading plan.

Summary

• Scott B. Ullem, CVP and Chief Financial Officer of Edwards Lifesciences Corp (EW), reported transactions on December 9, 2025.
• Ullem acquired 7,700 shares of common stock by exercising employee stock options at a price of $59.2567 per share.
• Concurrently, Ullem disposed of 7,700 shares of common stock at a weighted average sale price of $84.4691 per share, with trades ranging from $84.09 to $85.07.
• Both transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Ullem on July 29, 2025.
• Following these transactions, Ullem directly beneficially owns 39,898 shares of common stock.
• Additionally, 266,318 shares are indirectly beneficially owned by a Trust.
• Ullem also directly beneficially owns 39,000 employee stock options (right to acquire common stock) after the reported exercise.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions (option exercise and sale) executed under a pre-arranged 10b5-1 trading plan, which is a common practice for executive compensation and personal financial management. While a sale reduces direct ownership, the pre-planned nature mitigates negative sentiment, and the profitable exercise is a positive for the individual.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned activity and reducing speculation about market timing.
• The officer realized a profit from the option exercise, as the sale price ($84.4691) was significantly higher than the exercise price ($59.2567).

Negatives

• An insider selling shares, even under a pre-arranged plan, results in a reduction of their direct ownership stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction for an executive at a medical technology company. Such transactions are common across industries for executive compensation and personal financial management, and do not inherently reflect broader industry trends.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the pre-planned nature of the transaction suggests it is not based on new material information, thus limiting significant impact.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 details a routine insider transaction where the CFO exercised stock options and sold a portion of the resulting shares under a pre-arranged 10b5-1 trading plan. Such transactions are common for executive compensation and personal financial planning and typically do not signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Investors should consider broader company performance and market conditions.

Keywords

Edwards Lifesciences, EW, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Scott B. Ullem, CFO, 10b5-1 Plan